{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:10:45Z","timestamp":1778105445607,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Erasmus MC Fellowship grant","award":["EMCF20213"],"award-info":[{"award-number":["EMCF20213"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Early diagnosis of cancer is essential for improving patient outcomes. Metabolomics analysis has shown promise in detecting cancer and distinguishing its metastatic burdens in previous studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We hypothesized that metabolomics data can differentiate between people with and without cancer at a population level, uncovering new biomarkers and deepening our understanding of cancer metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 1,386 metabolites were measured by two commonly used metabolomics platforms: Nightingale and Metabolon, in baseline plasma samples from participants in the population-based Rotterdam Study, with sample sizes of 2,538 and 5,057, respectively. Logistic regression and competing risk Cox proportional hazards models were employed to examine associations between these metabolites and both baseline prevalent and incident during follow-up of all and cause-specific cancers. Statistical significance was defined by a false discovery rate (FDR)\u2009&lt;\u20090.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 654 cancer cases at baseline, and 618 new cases also occurred during follow-up of nearly 10 years. In the cross-sectional study, 68, 7, and 10 metabolites were significantly associated with prevalent blood, colorectal, and all cancer, after multivariate adjustment. In the longitudinal study, 19, 11, 2, 3, and 1 metabolites were significantly associated with incident blood, colorectal, lung, prostate, and all cancer, respectively. Among these, 17 and 2 metabolites were associated with both prevalent and incident blood and colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study indicates several circulating metabolites that are associated with different cancers. These metabolites may contribute to better understanding of the metabolic pathways of cancer and serve as biomarkers for early cancer diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11306-026-02397-6","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:32:39Z","timestamp":1771590759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma metabolomic signatures of all and cause-specific cancers: a multi-platform population-based study"],"prefix":"10.1007","volume":"22","author":[{"given":"Yu","family":"Shuai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikje","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Arfan","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Ghanbari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"2397_CR1","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1136\/gutjnl-2020-320723","volume":"70","author":"MG Adam","year":"2021","unstructured":"Adam, M. G., Beyer, G., Christiansen, N., Kamlage, B., Pilarsky, C., Distler, M., Fahlbusch, T., Chromik, A., Klein, F., Bahra, M., Uhl, W., Gr\u00fctzmann, R., Mahajan, U. M., Weiss, F. U., Mayerle, J., & Lerch, M. M. (2021). Identification and validation of a multivariable prediction model based on blood plasma and serum metabolomics for the distinction of chronic pancreatitis subjects from non-pancreas disease control subjects. Gut, 70, 2150\u20132158.","journal-title":"Gut"},{"key":"2397_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1161\/CIRCOUTCOMES.113.000675","volume":"7","author":"AO Akinkuolie","year":"2014","unstructured":"Akinkuolie, A. O., Paynter, N. P., Padmanabhan, L., & Mora, S. (2014). High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circulation. Cardiovascular Quality and Outcomes, 7, 55\u201363.","journal-title":"Circulation. Cardiovascular Quality and Outcomes"},{"key":"2397_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10552-017-0987-7","volume":"29","author":"SH Alford","year":"2018","unstructured":"Alford, S. H., Divine, G., Chao, C., Habel, L. A., Janakiraman, N., Wang, Y., Feigelson, H. S., Scholes, D., Roblin, D., Epstein, M. M., Engel, L., Havstad, S., Wells, K., Yood, M. U., Fortuny, J., Johnson, C. C., Cancer Research Network Lymphoma Study, G. (2018). Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes & Control, 29, 143\u2013156.","journal-title":"Cancer Causes & Control"},{"key":"2397_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1289\/ehp.1306615","volume":"121","author":"V Barry","year":"2013","unstructured":"Barry, V., Winquist, A., & Steenland, K. (2013). Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. Environmental Health Perspectives, 121, 1313\u20131318.","journal-title":"Environmental Health Perspectives"},{"key":"2397_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02553-4","volume":"20","author":"M Breeur","year":"2022","unstructured":"Breeur, M., Ferrari, P., Dossus, L., Jenab, M., Johansson, M., Rinaldi, S., Travis, R. C., His, M., Key, T. J., Schmidt, J. A., Overvad, K., Tj\u00f8nneland, A., Kyr\u00f8, C., Rothwell, J. A., Laouali, N., Severi, G., Kaaks, R., Katzke, V., Schulze, M. B., \u2026 Viallon, V. (2022). Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition. BMC Medicine, 20, Article 351.","journal-title":"BMC Medicine"},{"key":"2397_CR6","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","volume":"3","author":"RA Cairns","year":"2013","unstructured":"Cairns, R. A., & Mak, T. W. (2013). Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. Cancer Discovery, 3, 730\u201341.","journal-title":"Cancer Discovery"},{"key":"2397_CR7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","volume":"17","author":"L Camont","year":"2011","unstructured":"Camont, L., Chapman, M. J., & Kontush, A. (2011). Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends in Molecular Medicine, 17, 594\u2013603.","journal-title":"Trends in Molecular Medicine"},{"key":"2397_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030540","author":"T Choi","year":"2021","unstructured":"Choi, T., Choi, I. Y., Han, K., Jeong, S. M., Yoo, J. E., Rhee, S. Y., Park, Y. G., & Shin, D. W. (2021). Lipid level, lipid variability, and risk of multiple myeloma: A nationwide population-based study of 3,527,776 subjects. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13030540","journal-title":"Cancers (Basel)"},{"key":"2397_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., Marks, K. M., Prins, R. M., Ward, P. S., Yen, K. E., Liau, L. M., Rabinowitz, J. D., Cantley, L. C., Thompson, C. B., Vander Heiden, M. G., & Su, S. M. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739\u201344.","journal-title":"Nature"},{"key":"2397_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/alz.12180","volume":"17","author":"FA de Leeuw","year":"2021","unstructured":"de Leeuw, F. A., Karamuji\u0107-\u010comi\u0107, H., Tijms, B. M., Peeters, C. F. W., Kester, M. I., Scheltens, P., Ahmad, S., Vojinovic, D., Adams, H. H. H., Hankemeier, T., Bos, D., van der Lugt, A., Vernooij, M. W., Ikram, M. A., Amin, N., Barkhof, F., Teunissen, C. E., van Duijn, C. M., & van der Flier, W. M. (2021). Circulating metabolites are associated with brain atrophy and white matter hyperintensities. Alzheimer\u2019s & Dementia, 17, 205\u2013214.","journal-title":"Alzheimer's & Dementia"},{"key":"2397_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1042\/cs0890505","volume":"89","author":"S Dess\u00ec","year":"1995","unstructured":"Dess\u00ec, S., Batetta, B., Spano, O., Sanna, F., Tonello, M., Giacchino, M., Tessitore, L., Costelli, P., Baccino, F. M., Madon, E., et al. (1995). Clinical remission is associated with restoration of normal high-density lipoprotein cholesterol levels in children with malignancies. Clinical Science (London), 89, 505\u201310.","journal-title":"Clinical Science (London)"},{"key":"2397_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2023.1244457","volume":"5","author":"J Durham","year":"2023","unstructured":"Durham, J., Tessmann, J. W., Deng, P., Hennig, B., & Zaytseva, Y. Y. (2023). The role of perfluorooctane sulfonic acid (PFOS) exposure in inflammation of intestinal tissues and intestinal carcinogenesis. Frontiers in Toxicology, 5, Article 1244457.","journal-title":"Frontiers in Toxicology"},{"key":"2397_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105024","volume":"101","author":"R Harewood","year":"2024","unstructured":"Harewood, R., Rothwell, J. A., Be\u0161evi\u0107, J., Viallon, V., Achaintre, D., Gicquiau, A., Rinaldi, S., Wedekind, R., Prehn, C., Adamski, J., Schmidt, J. A., Jacobs, I., Tj\u00f8nneland, A., Olsen, A., Severi, G., Kaaks, R., Katzke, V., Schulze, M. B., Prada, M., \u2026 Gunter, M. J. (2024). Association between pre-diagnostic circulating lipid metabolites and colorectal cancer risk: A nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). EBioMedicine, 101, Article 105024.","journal-title":"EBioMedicine"},{"key":"2397_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14186","volume":"4","author":"S Huang","year":"2021","unstructured":"Huang, S., Guo, Y., Li, Z. W., Shui, G., Tian, H., Li, B. W., Kadeerhan, G., Li, Z. X., Li, X., Zhang, Y., Zhou, T., You, W. C., Pan, K. F., & Li, W. Q. (2021). Identification and validation of plasma metabolomic signatures in precancerous gastric lesions that progress to cancer. JAMA Network Open, 4, Article e2114186.","journal-title":"JAMA Network Open"},{"key":"2397_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10654-020-00640-5","volume":"35","author":"MA Ikram","year":"2020","unstructured":"Ikram, M. A., Brusselle, G., Ghanbari, M., Goedegebure, A., Ikram, M. K., Kavousi, M., Kieboom, B. C. T., Klaver, C. C. W., de Knegt, R. J., Luik, A. I., Nijsten, T. E. C., Peeters, R. P., van Rooij, F. J. A., Stricker, B. H., Uitterlinden, A. G., Vernooij, M. W., & Voortman, T. (2020). Objectives, design and main findings until 2020 from the Rotterdam Study. European Journal of Epidemiology, 35, 483\u2013517.","journal-title":"European Journal of Epidemiology"},{"key":"2397_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-45","volume":"14","author":"KE Innes","year":"2014","unstructured":"Innes, K. E., Wimsatt, J. H., Frisbee, S., & Ducatman, A. M. (2014). Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population. BMC Cancer, 14, Article 45.","journal-title":"BMC Cancer"},{"key":"2397_CR17","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/s41375-020-01081-5","volume":"35","author":"SM Jeong","year":"2021","unstructured":"Jeong, S. M., Choi, T., Kim, D., Han, K., Kim, S. J., Rhee, S. Y., Giovannucci, E. L., & Shin, D. W. (2021). Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. Leukemia, 35, 1356\u20131364.","journal-title":"Leukemia"},{"key":"2397_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrm.2016.25","volume":"17","author":"CH Johnson","year":"2016","unstructured":"Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016). Metabolomics: Beyond biomarkers and towards mechanisms. Nature Reviews Molecular Cell Biology, 17, 451\u2013459.","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"2397_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2478\/s11658-008-0014-9","volume":"13","author":"M Kuliszkiewicz-Janus","year":"2008","unstructured":"Kuliszkiewicz-Janus, M., Ma\u0142ecki, R., & Mohamed, A. S. (2008). Lipid changes occuring in the course of hematological cancers. Cellular & Molecular Biology Letters, 13, 465\u2013474.","journal-title":"Cellular & Molecular Biology Letters"},{"key":"2397_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638288","volume":"11","author":"V Lazaris","year":"2021","unstructured":"Lazaris, V., Hatziri, A., Symeonidis, A., & Kypreos, K. E. (2021). The lipoprotein transport system in the pathogenesis of multiple myeloma: Advances and challenges. Frontiers in Oncology, 11, Article 638288.","journal-title":"Frontiers in Oncology"},{"key":"2397_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/ajcn\/80.1.204","volume":"80","author":"MF Leitzmann","year":"2004","unstructured":"Leitzmann, M. F., Stampfer, M. J., Michaud, D. S., Augustsson, K., Colditz, G. C., Willett, W. C., & Giovannucci, E. L. (2004). Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. American Journal of Clinical Nutrition, 80, 204\u2013216.","journal-title":"American Journal of Clinical Nutrition"},{"key":"2397_CR22","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1136\/gutjnl-2021-325851","volume":"71","author":"C Li","year":"2022","unstructured":"Li, C., Wang, Y., Liu, D., Wong, C. C., Coker, O. O., Zhang, X., Liu, C., Zhou, Y., Liu, Y., Kang, W., To, K. F., Sung, J. J., & Yu, J. (2022a). Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut, 71, 2253\u20132265.","journal-title":"Gut"},{"key":"2397_CR23","doi-asserted-by":"publisher","first-page":"112217","DOI":"10.1016\/j.envres.2021.112217","volume":"204","author":"H Li","year":"2022","unstructured":"Li, H., Hammarstrand, S., Midberg, B., Xu, Y., Li, Y., Olsson, D. S., Fletcher, T., Jakobsson, K., & Andersson, E. M. (2022b). Cancer incidence in a Swedish cohort with high exposure to perfluoroalkyl substances in drinking water. Environmental Research, 204, 112217.","journal-title":"Environmental Research"},{"key":"2397_CR24","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/eurheartj\/ehaa209","volume":"41","author":"J Li","year":"2020","unstructured":"Li, J., Guasch-Ferr\u00e9, M., Chung, W., Ruiz-Canela, M., Toledo, E., Corella, D., Bhupathiraju, S. N., Tobias, D. K., Tabung, F. K., Hu, J., Zhao, T., Turman, C., Feng, Y. A., Clish, C. B., Mucci, L., Eliassen, A. H., Costenbader, K. H., Karlson, E. W., Wolpin, B. M., \u2026 Liang, L. (2020). The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. European Heart Journal, 41, 2645\u20132656.","journal-title":"European Heart Journal"},{"key":"2397_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/gutjnl-2021-325189","volume":"71","author":"J Liu","year":"2022","unstructured":"Liu, J., Geng, W., Sun, H., Liu, C., Huang, F., Cao, J., Xia, L., Zhao, H., Zhai, J., Li, Q., Zhang, X., Kuang, M., Shen, S., Xia, Q., Wong, V. W., & Yu, J. (2022). Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma. Gut, 71, 1203\u20131213.","journal-title":"Gut"},{"key":"2397_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104805","volume":"156","author":"X Luo","year":"2020","unstructured":"Luo, X., Liu, J., Wang, H., & Lu, H. (2020). Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Pharmacological Research, 156, Article 104805.","journal-title":"Pharmacological Research"},{"key":"2397_CR27","first-page":"146","volume":"36","author":"E Ozturk","year":"2021","unstructured":"Ozturk, E. (2021). The relationship between hematological malignancy and lipid profile. Medeniyet Medical Journal, 36, 146\u2013151.","journal-title":"Medeniyet Medical Journal"},{"key":"2397_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00963-6","volume":"13","author":"KM Pedersen","year":"2020","unstructured":"Pedersen, K. M., \u00c7olak, Y., Bojesen, S. E., & Nordestgaard, B. G. (2020). Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. Journal Of Hematology & Oncology, 13, Article 129.","journal-title":"Journal Of Hematology & Oncology"},{"key":"2397_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2023.108198","volume":"180","author":"J Rhee","year":"2023","unstructured":"Rhee, J., Loftfield, E., Albanes, D., Layne, T. M., Stolzenberg-Solomon, R., Liao, L. M., Playdon, M. C., Berndt, S. I., Sampson, J. N., Freedman, N. D., Moore, S. C., & Purdue, M. P. (2023). A metabolomic investigation of serum perfluorooctane sulfonate and perfluorooctanoate. Environment International, 180, Article 108198.","journal-title":"Environment International"},{"key":"2397_CR30","first-page":"1353","volume":"11","author":"M Saadatian-Elahi","year":"2002","unstructured":"Saadatian-Elahi, M., Toniolo, P., Ferrari, P., Goudable, J., Akhmedkhanov, A., Zeleniuch-Jacquotte, A., & Riboli, E. (2002). Serum fatty acids and risk of breast cancer in a nested case-control study of the New York university women\u2019s health study. Cancer Epidemiology, Biomarkers & Prevention, 11, 1353\u20131360.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"key":"2397_CR31","doi-asserted-by":"crossref","unstructured":"Schiliro, C., & Firestein, B. L. (2021). Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells 10.","DOI":"10.3390\/cells10051056"},{"key":"2397_CR32","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1039\/b910205a","volume":"134","author":"P Soininen","year":"2009","unstructured":"Soininen, P., Kangas, A. J., W\u00fcrtz, P., Tukiainen, T., Tynkkynen, T., Laatikainen, R., J\u00e4rvelin, M. R., K\u00e4h\u00f6nen, M., Lehtim\u00e4ki, T., Viikari, J., Raitakari, O. T., Savolainen, M. J., & Ala-Korpela, M. (2009). High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst, 134, 1781\u20131785.","journal-title":"Analyst"},{"key":"2397_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01602-x","volume":"25","author":"VL Stevens","year":"2023","unstructured":"Stevens, V. L., Carter, B. D., Jacobs, E. J., McCullough, M. L., Teras, L. R., & Wang, Y. (2023). A prospective case-cohort analysis of plasma metabolites and breast cancer risk. Breast Cancer Research, 25, Article 5.","journal-title":"Breast Cancer Research"},{"key":"2397_CR34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023). High-density lipoprotein revisited: Biological functions and clinical relevance. European Heart Journal, 44, 1394\u20131407.","journal-title":"European Heart Journal"},{"key":"2397_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","volume":"39","author":"LB Wang","year":"2021","unstructured":"Wang, L. B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., Stathias, V., Cornwell, M., Petralia, F., Wu, Y., Reva, B., Krug, K., Pugliese, P., Kawaler, E., Olsen, L. K., \u2026 Clinical Proteomic Tumor Analysis, C. (2021). Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell, 39, 509-528 e20.","journal-title":"Cancer Cell"},{"key":"2397_CR36","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1186\/s12885-016-2861-5","volume":"16","author":"J Wimsatt","year":"2016","unstructured":"Wimsatt, J., Villers, M., Thomas, L., Kamarec, S., Montgomery, C., Yeung, L. W., Hu, Y., & Innes, K. (2016). Oral perfluorooctane sulfonate (PFOS) lessens tumor development in the APC(min) mouse model of spontaneous familial adenomatous polyposis. BMC Cancer, 16, 942.","journal-title":"BMC Cancer"},{"key":"2397_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","volume":"32","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y., Ma, D., Yang, Y. S., Yang, F., Ding, J. H., Gong, Y., Jiang, L., Ge, L. P., Wu, S. Y., Yu, Q., Zhang, Q., Bertucci, F., Sun, Q., Hu, X., Li, D. Q., Shao, Z. M., & Jiang, Y. Z. (2022). Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Research, 32, 477\u2013490.","journal-title":"Cell Research"},{"key":"2397_CR38","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-019-0458-7","volume":"25","author":"S Yachida","year":"2019","unstructured":"Yachida, S., Mizutani, S., Shiroma, H., Shiba, S., Nakajima, T., Sakamoto, T., Watanabe, H., Masuda, K., Nishimoto, Y., Kubo, M., Hosoda, F., Rokutan, H., Matsumoto, M., Takamaru, H., Yamada, M., Matsuda, T., Iwasaki, M., Yamaji, T., Yachida, T., \u2026 Yamada, T. (2019). Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nature Medicine, 25, 968\u2013976.","journal-title":"Nature Medicine"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-026-02397-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11306-026-02397-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-026-02397-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:21:06Z","timestamp":1778102466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11306-026-02397-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2397"],"URL":"https:\/\/doi.org\/10.1007\/s11306-026-02397-6","relation":{},"ISSN":["1573-3890"],"issn-type":[{"value":"1573-3890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has been conducted within the Rotterdam study, which was approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR;\n                      \n                      )) and into the WHO International Clinical Trials Registry Platform (ICTRP;\n                      \n                      ) under shared catalogue number NTR6831.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"27"}}